

- immunizes mice. *Proc. Natl. Acad. Sci. U. S. A.* 101, 6641–6646
- 56 Yang, Z.Y. *et al.* (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 428, 561–564
- 57 McCaffrey, A.P. *et al.* (2003) Inhibition of hepatitis B virus in mice by RNA interference. *Nat. Biotechnol.* 21, 639–644
- 58 Zhang, R. *et al.* (2003) Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. *Chin Med J (Engl)* 116, 1262–1264
- 59 Zhang, X.W. and Yap, Y.L. (2004) Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. *Bioorg. Med. Chem.* 12, 2517–2521
- 60 Wang, Z. *et al.* (2004) Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. *J. Virol.* 78, 7523–7527
- 61 Sledz, C.A. *et al.* (2003) Activation of the interferon system by short-interfering RNAs. *Nat. Cell Biol.* 5, 834–839
- 62 Opalinska, J.B. and Gewirtz, A.M. (2002) Nucleic-acid therapeutics: basic principles and recent applications. *Nat. Rev. Drug Discov.* 1, 503–514
- 63 Yeh, S.H. *et al.* (2004) Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. *Proc. Natl. Acad. Sci. U. S. A.* 101, 2542–2547
- 64 Chinese, S.M.E.C. (2004) Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. *Science* 303, 1666–1669
- 65 von Grotthuss, M. *et al.* (2003) mRNA cap-1 methyltransferase in the SARS genome. *Cell* 113, 701–702
- 66 Ivanov, K.A. *et al.* (2004) Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. *J. Virol.* 78, 5619–5632
- 67 Kao, R.Y. *et al.* (2004) Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. *Chem. Biol.* 11, 1293–1299
- 68 Xu, X. *et al.* (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. *Nucleic Acids Res.* 31, 7117–7130
- 69 Barnard, D.L. *et al.* (2004) Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antivir. Chem. Chemother.* 15, 15–22
- 70 Chen, F. *et al.* (2004) *In vitro* susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. *J. Clin. Virol.* 31, 69–75
- 71 Leong, H.N. *et al.* (2004) Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. *Trop. Med. Int. Health* 9, 923–927
- 72 Wang, W.K. *et al.* (2004) Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. *Clin. Infect. Dis.* 39, 1071–1075
- 73 Anand, K. *et al.* (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* 300, 1763–1767
- 74 Yang, H. *et al.* (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proc. Natl. Acad. Sci. U. S. A.* 100, 13190–13195
- 75 Hillisch, A. *et al.* (2004) Utility of homology models in the drug discovery process. *Drug Discov. Today* 9, 659–669
- 76 Kao, R.Y. *et al.* (2004) Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. *FEBS Lett.* 576, 325–330
- 77 Blanchard, J.E. *et al.* (2004) High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase. *Chem. Biol.* 11, 1445–1453
- 78 Yamamoto, N. *et al.* (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. *Biochem. Biophys. Res. Commun.* 318, 719–725

Corrigendum

In the recent review published by Nassar *et al.* in *Drug Discovery Today (Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability)*, Vol. 9, Issue 23, 1 December 2004, Pages 1020–1028) an important literature citation was omitted from the published reference list. The details of this article, including a weblink to a free article download, are provided below. The editorial team of *Drug Discovery Today* would like to apologise for this omission.

Metabolism-driven optimization of pharmacokinetics

Current Drug Discovery, May 2004, Pages 17–22

Alan J. Henderson and Peter R. Guzzo

<http://www.currentdrugdiscovery.com/2004/may.html>